Print

Purpose

The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM

Condition

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Is an adult patient with a confirmed diagnosis of T2DM - Has a body mass index (BMI) of ≥25 kg/m^2 and <39.9 kg/m^2 - Has a hemoglobin A1c (HbA1c) ≥6.5% to <10.5% - Is on a stable dose of metformin

Exclusion Criteria

  • Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results - Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods Note: other protocol defined inclusion/exclusion criteria apply

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
ALN-4324 		Participants will be administered a single dose of ALN-4324.
  • Drug: ALN-4324
    ALN-4324 will be administered subcutaneously (SC).
Placebo Comparator
Placebo 		Participants will be administered a single dose of placebo.
  • Drug: Placebo
    Placebo will be administered SC.

Recruiting Locations

Clinical Trial Site
Chula Vista, California 91911

More Details

Status
Recruiting
Sponsor
Alnylam Pharmaceuticals

Study Contact

Alnylam Clinical Trial Information Line
1-877-ALNYLAM
clinicaltrials@alnylam.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.